A New Platform for Developing a Compound Against Herpes Simplex Virus. This project aims to further explore the research team’s recent fundamental discovery of a protein found naturally in an Australian abalone that inhibits viral entry by blocking three key viral glycoproteins. We would aim to utilise this knowledge towards development of a new class of therapeutics against Herpes simplex viruses (HSV) and their consequent infections. The new therapeutics could overcome the low bioavailability ....A New Platform for Developing a Compound Against Herpes Simplex Virus. This project aims to further explore the research team’s recent fundamental discovery of a protein found naturally in an Australian abalone that inhibits viral entry by blocking three key viral glycoproteins. We would aim to utilise this knowledge towards development of a new class of therapeutics against Herpes simplex viruses (HSV) and their consequent infections. The new therapeutics could overcome the low bioavailability of current drugs and thus significantly shorten the recurrence period. Such new drugs may have broad applicability.Read moreRead less
Specific gene inhibition through functional genomics and high through-put small molecule screening. This project will utilise functional genomic technologies in an attempt to identify genes in childhood neuroblastoma as potential candidates for the future development of molecular-targeted gene therapy. By screening large 'libraries' of chemical compounds, we aim to identify compounds with the ability to specifically inhibit these gene targets. This project will therefore define novel molecular t ....Specific gene inhibition through functional genomics and high through-put small molecule screening. This project will utilise functional genomic technologies in an attempt to identify genes in childhood neuroblastoma as potential candidates for the future development of molecular-targeted gene therapy. By screening large 'libraries' of chemical compounds, we aim to identify compounds with the ability to specifically inhibit these gene targets. This project will therefore define novel molecular targets and possibly facilitate the future development of new therapeutic approaches to treating neuroblastoma. In addition, the project will develop know-how that can be utilised by both the industry partner and the broader research community and will introduce to Australian science novel techniques and skills. Read moreRead less
Industrial Transformation Training Centres - Grant ID: IC160100027
Funder
Australian Research Council
Funding Amount
$4,340,802.00
Summary
ARC Training Centre for Biopharmaceutical Innovation. ARC Training Centre for Biopharmaceutical Innovation. This centre aims to transform Australia’s growing biopharmaceutical industry, an advanced manufacturing capability, by training specialist biotechnologists and bioengineers. It expects the research and development outputs will create new biopharmaceuticals and antibody-based reagents, enhanced production methods, improved manufacturing capabilities and a cohort of specialist scientists. Ne ....ARC Training Centre for Biopharmaceutical Innovation. ARC Training Centre for Biopharmaceutical Innovation. This centre aims to transform Australia’s growing biopharmaceutical industry, an advanced manufacturing capability, by training specialist biotechnologists and bioengineers. It expects the research and development outputs will create new biopharmaceuticals and antibody-based reagents, enhanced production methods, improved manufacturing capabilities and a cohort of specialist scientists. New biopharmaceuticals are expected to benefit the Australian economy and provide new therapeutic options for better health outcomes. Industry-driven research projects will also provide industry-ready graduates who can drive future growth in the sector.Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0454209
Funder
Australian Research Council
Funding Amount
$126,326.00
Summary
A Glycobiology Facility for Glycoconjugate Analysis and Oligosaccharide Sequencing. The carbohydrate moiety of glycoconjugates plays an important role in their function and metabolism. Advances in glycan analytical and oligosaccharide sequencing techniques offer tremendous potential for the application of glycobiology to biotechnology, cell biology and medicine. This application aims to establish a Glycobiology Facility dedicated to glycoconjugate analysis and oligosaccharide sequencing. Funds a ....A Glycobiology Facility for Glycoconjugate Analysis and Oligosaccharide Sequencing. The carbohydrate moiety of glycoconjugates plays an important role in their function and metabolism. Advances in glycan analytical and oligosaccharide sequencing techniques offer tremendous potential for the application of glycobiology to biotechnology, cell biology and medicine. This application aims to establish a Glycobiology Facility dedicated to glycoconjugate analysis and oligosaccharide sequencing. Funds are requested for state of the art HPLC equipment, associated equipment and reagents for glycan purification/labelling, and a staff member, that are all essential to establish this technology in Australia. The Facility will support $25 million of existing research; approximately half of which is derived from ARC.Read moreRead less
Industrial Transformation Research Hubs - Grant ID: IH190100021
Funder
Australian Research Council
Funding Amount
$4,999,540.00
Summary
ARC Research Hub to Combat Antimicrobial Resistance. The ARC ITRP Research Hub to Combat Antimicrobial Resistance takes on the global challenge of antimicrobial resistance (AMR) for Australia through a world-first partnership between industry, researchers, and end users. The AMR Hub fosters a pre-commercialisation environment to address both social and laboratory-based preclinical challenges to provide a highly integrated diagnostic, pharmaceutical and end user solution to the problem of AMR. A ....ARC Research Hub to Combat Antimicrobial Resistance. The ARC ITRP Research Hub to Combat Antimicrobial Resistance takes on the global challenge of antimicrobial resistance (AMR) for Australia through a world-first partnership between industry, researchers, and end users. The AMR Hub fosters a pre-commercialisation environment to address both social and laboratory-based preclinical challenges to provide a highly integrated diagnostic, pharmaceutical and end user solution to the problem of AMR. A goal of the Hub is to support the development of new molecular diagnostic technology, improve the processes for identifying potential antibiotic compounds and assess and advise on antimicrobial stewardship with a vision to transform social and health outcomes globally.Read moreRead less